The last few years has seen a significant advance in our understanding of the role ERK5 in certain malignancies, most notably in melanoma where components of the entire core pathway are amplified or upregulated and where ERK5 activation can drive resistance to BRAF, MEK or ERK1/2 inhibitors. Here, MAP2K7 is linked to melanoma.